Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
08/08/20 12:55 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jul 29 2020
Summary ToggleAdverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
- Jul 21 2020
Summary ToggleAdverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
- Jul 13 2020
Summary ToggleAdverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
- Jul 6 2020
Summary ToggleAdverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD